WCLC 2021 | Efficacy of datopotamab deruxtecan, a TROP2 ADC, in aNSCLC

Alex Spira, MD, PhD, FACP, Virginia Cancer Specialists, Fairfax, VA, shares the updated results of a trial of datopotamab deruxtecan (Dato-DXd; DS-1062) use in non-small cell lung cancer (NSCLC), conducted as part of the Phase I TROPION-PanTumor01 study (NCT03401385). Dato-DXd is an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) which is overexpressed in NSCLC. In total, 133 patients with advanced/metastatic relapsed/refractory (R/R) NSCLC were enrolled and treated at various dose levels to determine the maximum tolerated dose. A promising complete/partial response rate and dose control rate were achieved, and the toxicity was manageable. Efficacy and safety considerations established the recommended future dose as 6mg/kg. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.